SlideShare a Scribd company logo
1 of 23
Download to read offline
E X T R A C O R P O R E A L
R E M O V A L
O F D R U G S
D R . R A M E S H B H A N D A R I
A S S T. P R O F E S S O R
K L E C O L L E G E O F P H A R M A C Y, B E L A G AV I
INTRODUCTION
• Patients with end-stage renal disease (ESRD) and those who have
become intoxicated with a drug as a result of drug overdose require
supportive treatment to remove the accumulated drug and its
metabolites.
• Several methods are available for the extracorporeal removal of
drugs, including:
 Dialysis,
 Hemoperfusion, and
 Hemofiltration.
INTRODUCTION
• Objective:
 rapidly remove the undesirable drugs and metabolites from the
body without disturbing the fluid and electrolyte balance in the
patient.
• Patients with impaired renal function may be taking other
medication concurrently. For these patients, dosage adjustment may
be needed to replace drug loss during extracorporeal drug and
metabolite removal.
DIALYSIS
• Dialysis is an artificial process in which the accumulated drugs or
waste metabolites is removed by diffusion from the body into the
dialysis fluid.
• Two common dialysis treatments are hemodialysis and peritoneal
dialysis.
DIALYSIS
• The principle:
Uremic blood or fluid is equilibrated with the dialysis fluid across a
dialysis membrane, waste metabolites from the patient’s blood or
fluid diffuse into the dialysis fluid and are removed. The dialysate is
balanced with electrolytes and with respect to osmotic pressure. The
dialysate contains water, dextrose, electrolytes (potassium, sodium,
chloride, bicarbonate, acetate, calcium, etc), and other elements
similar to normal body fluids without the toxins.
HEMODIALYSIS
• uses a dialysis machine and filters blood through an artificial
membrane.
• requires access to the blood vessels to allow the blood to flow to the
dialysis machine and back to the body.
• For temporary access, a shunt is created in the arm, with one tube
inserted into an artery and another tube inserted into a vein. The
tubes are joined above the skin.
• For permanent access to the blood vessels, an arteriovenous fistula
or graft is created by a surgical procedure to allow access to the
artery and vein.
HEMODIALYSIS
• At the start of the
hemodialysis
procedure, an arterial
needle allows the
blood to flow to the
dialysis machine, and
blood is returned to the
patient to the venous
side. Heparin is used
to prevent blood
clotting during the
dialysis period.
HEMODIALYSIS
Indications:
• When rapid removal of the drug from the body is important, as in
overdose or poisoning.
• End-stage renal failure.
• Early dialysis is appropriate for patients with acute renal failure in
whom resumption of renal function can be expected.
• Renal transplanted.
HEMODIALYSIS
Drugs widely
distributed are
dialyzed more
slowly.
Drugs with
largeVd
Less than 500 are
easily dialyzed.
Molecular
Weight
Highly bound
drugs are not
dialyzed. (eg
Propanolol)
Protein binding
Insoluble or fat
soluble drugs are
not dialyzed. (eg:
Glutethimide)
Water Solubility
Factors Affecting Dialyzabillity of the drugs
HEMODIALYSIS
Factors Affecting Dialyzability of the drugs
Characteristics of the
dialysis machine
Duration
and
frequency
Transmembrane
pressure
Dialysis
membrane
Dialysate
Blood
flow
rate
PERITONEAL DIALYSIS
• Peritoneal dialysis uses the peritoneal membrane in the abdomen as the
filter.
• The peritoneum membrane provides a large natural surface area for
diffusion of approximately 1–2 m2 in adults; it is permeable to solutes
of molecular weights ≤30,000 Dalton.
• However, only a small portion of the total splanchnic blood flow (70
mL/min out of 1200 mL/min at rest) comes into contact with the
peritoneum and gets dialyzed.
• Placement of a peritoneal catheter is surgically simpler than
hemodialysis and does not require vascular surgery and heparinization
PERITONEAL DIALYSIS
• The dialysis fluid is pumped into
the peritoneal cavity, where
waste metabolites in the body
fluid are discharged rapidly. The
dialysate is drained and fresh
dialysate is reinstilled and then
drained periodically.
• Slower drug clearance rates are
obtained with peritoneal dialysis
compared to hemodialysis, and
thus longer dialysis time is
required.
Fig: Side view of Peritoneal dialysis
CONTINUOUS AMBULATORY PERITONEAL
DIALYSIS
• Most common form of peritoneal dialysis.
• Many diabetic patients become uremic as a result of lack of
control of their disease so the objective is to remove
accumulated urea and other metabolic waste in the body.
CONTINUOUS AMBULATORY PERITONEAL
DIALYSIS
 About 2 L of dialysis fluid is instilled into the peritoneal cavity of
the patient through a surgically placed resident catheter.
 The catheter is sealed and the patient is able to continue in an
ambulatory mode.
 Every 4–6 hours, the fluid is emptied from the peritoneal cavity
and replaced with fresh dialysis fluid.
 The technique uses about 2 L of dialysis fluid; it does not require a
dialysis machine and can be performed at home.
HEMOPERFUSION
 Hemoperfusion is the process of removing drug by passing the
blood from the patient through an adsorbent material and back to
the patient.
 Hemoperfusion is a useful procedure for rapid drug removal in
accidental poisoning and drug overdose.
 Because the drug molecules in the blood are in direct contact with
the adsorbent material, any molecule that has great affinity for the
adsorbent material will be removed.
HEMOPERFUSION
 The two main adsorbents used in hemoperfusion include
(1) activated charcoal, which adsorbs both polar and nonpolar
drug, and (2) Amberlite resins.
 Amberlite resins, such as Amberlite XAD-2 and Amberlite XAD-
4, are available as insoluble polymeric beads, with each bead
containing an agglomerate of cross-linked polystyrene
microspheres.
 The Amberlite resins have a greater affinity for nonpolar organic
molecules than activated charcoal.
HEMOPERFUSION
 The important factors for drug removal by hemoperfusion include
• affinity of the drug for the adsorbent,
• surface area of the adsorbent,
• absorptive capacity of the adsorbent,
• rate of blood flow through the adsorbent, and
• the equilibration rate of the drug from the peripheral tissue into
the blood.
HEMOFILTRATION
 An alternative to hemodialysis and hemoperfusion is
hemofiltration.
 Hemofiltration is a process by which fluids, electrolytes, and
small-molecular-weight substances are removed from the blood
by means of low-pressure flow through hollow artificial fibers or
flat-plate membranes.
 Because fluid is also filtered out of the plasma during
hemofiltration, replacement fluid is administered to the patient for
volume replacement.
HEMOFILTRATION
 Hemofiltration is a slow, continuous filtration process that
removes nonprotein-bound small molecules from the blood by
convective mass transport.
 The clearance of the drug depends on the sieving coefficient and
ultrafiltration rate. Hemofiltration provides a creatinine clearance
of approximately 10 mL/min and may have limited use for drugs
that are widely distributed in the body, such as aminoglycosides,
cephalosporines, and acyclovir.
 A major problem with this method is the formation of blood clots
within the hollow filter fibres.
CONTINUOUS RENAL REPLACEMENT THERAPY
• Because of the initial loss of fluid that results during
hemofiltration, intermittent hemofiltration results in
concentration of red blood cells in the resulting reduced
plasma volume.
• Therefore, blood becomes more viscous with a high
hematocrit and high colloid osmotic pressure at the distal
end of the hemofilter. Predilution may be used to
circumvent this problem, but this method is rarely used
because of cost and inefficiency.
CONTINUOUS RENAL REPLACEMENT THERAPY
• Continuous replacement therapy allows ongoing removal
of fluid and toxins by relying on a patient’s own blood
pressure to pump blood through a filter.
• The continuous filtration is better tolerated by patients
than intermittent therapy and provides optimal control of
circulating volumes and ongoing toxin removal.
CONTINUOUS RENAL REPLACEMENT THERAPY
Continuous renal replacement therapy (CRRT)
includes:
 Continuous veno-venous hemofiltration (CVVH)
and
 Continuous arteriovenous hemofiltration (CAVH)
Extracorporeal removal of drugs

More Related Content

What's hot

Effect of liver disease on pharmacokinetics
 Effect of liver disease on pharmacokinetics  Effect of liver disease on pharmacokinetics
Effect of liver disease on pharmacokinetics pavithra vinayak
 
Drug Utilization review
Drug Utilization review Drug Utilization review
Drug Utilization review Pooja Panjwani
 
Determination of dose and dosing interval
Determination of dose and dosing intervalDetermination of dose and dosing interval
Determination of dose and dosing intervalDr. Ramesh Bhandari
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide sharejavvadhasan
 
Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.pavithra vinayak
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimenDr. Ramesh Bhandari
 
Measurement of outcome v5
Measurement  of outcome v5Measurement  of outcome v5
Measurement of outcome v5aiswarya thomas
 
6. population pharmacokinetics
6. population pharmacokinetics6. population pharmacokinetics
6. population pharmacokineticsPARUL UNIVERSITY
 
Effects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsEffects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsDr. Ramesh Bhandari
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsDr Htet
 
DRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONaishuanju
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersAbel C. Mathew
 
Dose adjustment in renal disease
Dose adjustment in renal diseaseDose adjustment in renal disease
Dose adjustment in renal diseaseAreej Abu Hanieh
 
TDM of drugs used in cardiovascular diseases
TDM of drugs used in cardiovascular diseasesTDM of drugs used in cardiovascular diseases
TDM of drugs used in cardiovascular diseasesDr. Ramesh Bhandari
 
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its applicationClinical pharmacokinetics and its application
Clinical pharmacokinetics and its applicationpavithra vinayak
 
Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics Areej Abu Hanieh
 
Pharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlationPharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlationDr. Ramesh Bhandari
 
Individualisation and optimization of drug dosing regimen
Individualisation and optimization of drug dosing regimenIndividualisation and optimization of drug dosing regimen
Individualisation and optimization of drug dosing regimenJyoti Nautiyal
 

What's hot (20)

Effect of liver disease on pharmacokinetics
 Effect of liver disease on pharmacokinetics  Effect of liver disease on pharmacokinetics
Effect of liver disease on pharmacokinetics
 
Dose in uremia
Dose in uremiaDose in uremia
Dose in uremia
 
TDM of psychiatric drugs
TDM of psychiatric drugsTDM of psychiatric drugs
TDM of psychiatric drugs
 
Drug Utilization review
Drug Utilization review Drug Utilization review
Drug Utilization review
 
Determination of dose and dosing interval
Determination of dose and dosing intervalDetermination of dose and dosing interval
Determination of dose and dosing interval
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide share
 
Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.Genetic polymorphism in drug transport and drug targets.
Genetic polymorphism in drug transport and drug targets.
 
Individualization of drug dosage regimen
Individualization of drug dosage regimenIndividualization of drug dosage regimen
Individualization of drug dosage regimen
 
Measurement of outcome v5
Measurement  of outcome v5Measurement  of outcome v5
Measurement of outcome v5
 
6. population pharmacokinetics
6. population pharmacokinetics6. population pharmacokinetics
6. population pharmacokinetics
 
Effects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokineticsEffects of liver diseases on pharmacokinetics
Effects of liver diseases on pharmacokinetics
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerations
 
DRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION
DRUG UTILIZATION EVALUATION
 
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disordersTherapeutic drug monitoring (TDM) of drugs used in seizure disorders
Therapeutic drug monitoring (TDM) of drugs used in seizure disorders
 
Dose adjustment in renal disease
Dose adjustment in renal diseaseDose adjustment in renal disease
Dose adjustment in renal disease
 
TDM of drugs used in cardiovascular diseases
TDM of drugs used in cardiovascular diseasesTDM of drugs used in cardiovascular diseases
TDM of drugs used in cardiovascular diseases
 
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its applicationClinical pharmacokinetics and its application
Clinical pharmacokinetics and its application
 
Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics Effects of Liver disease on Pharmacokinetics
Effects of Liver disease on Pharmacokinetics
 
Pharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlationPharmacokinetic and pharmacodynamic correlation
Pharmacokinetic and pharmacodynamic correlation
 
Individualisation and optimization of drug dosing regimen
Individualisation and optimization of drug dosing regimenIndividualisation and optimization of drug dosing regimen
Individualisation and optimization of drug dosing regimen
 

Similar to Extracorporeal removal of drugs

Continuous renal replacement therapy
Continuous renal replacement therapyContinuous renal replacement therapy
Continuous renal replacement therapysaheli chakraborty
 
Continuous Renal Replacement Therapy
Continuous Renal Replacement TherapyContinuous Renal Replacement Therapy
Continuous Renal Replacement TherapyDhanya Raghu
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapynagarjunanri
 
Renal teplacement therapy / Dialysis
Renal teplacement therapy / DialysisRenal teplacement therapy / Dialysis
Renal teplacement therapy / DialysisDr. Sharad Chand
 
Hemodialysis: management of chronic kidney disease
Hemodialysis: management of chronic kidney diseaseHemodialysis: management of chronic kidney disease
Hemodialysis: management of chronic kidney diseaseSapana Shrestha
 
Continuous renal replacement therapy in icu Crrt 2
 Continuous renal replacement therapy in icu Crrt  2 Continuous renal replacement therapy in icu Crrt  2
Continuous renal replacement therapy in icu Crrt 2samirelansary
 
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt 2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt  2CONTINUOUS RENAL REPLACEMENT THERAPY Crrt  2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt 2samirelansary
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapyaratimohan
 
Renal replacement therapies(RRT) - Medicine - RDT
Renal replacement therapies(RRT) - Medicine - RDTRenal replacement therapies(RRT) - Medicine - RDT
Renal replacement therapies(RRT) - Medicine - RDTDr. Salman Ansari
 

Similar to Extracorporeal removal of drugs (20)

Extracorporeal removal of drugs
Extracorporeal removal of drugsExtracorporeal removal of drugs
Extracorporeal removal of drugs
 
Renal dialysis
Renal dialysisRenal dialysis
Renal dialysis
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Extracorporeal tech
Extracorporeal techExtracorporeal tech
Extracorporeal tech
 
Continuous renal replacement therapy
Continuous renal replacement therapyContinuous renal replacement therapy
Continuous renal replacement therapy
 
Continuous Renal Replacement Therapy
Continuous Renal Replacement TherapyContinuous Renal Replacement Therapy
Continuous Renal Replacement Therapy
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
Hemodialysis
Hemodialysis Hemodialysis
Hemodialysis
 
Seminar on CRRT
Seminar on CRRTSeminar on CRRT
Seminar on CRRT
 
Renal teplacement therapy / Dialysis
Renal teplacement therapy / DialysisRenal teplacement therapy / Dialysis
Renal teplacement therapy / Dialysis
 
HEMODIALYSIS MACHINE
HEMODIALYSIS MACHINEHEMODIALYSIS MACHINE
HEMODIALYSIS MACHINE
 
Hemodialysis: management of chronic kidney disease
Hemodialysis: management of chronic kidney diseaseHemodialysis: management of chronic kidney disease
Hemodialysis: management of chronic kidney disease
 
contious Renal replacement therapy
contious Renal replacement therapycontious Renal replacement therapy
contious Renal replacement therapy
 
Continuous renal replacement therapy in icu Crrt 2
 Continuous renal replacement therapy in icu Crrt  2 Continuous renal replacement therapy in icu Crrt  2
Continuous renal replacement therapy in icu Crrt 2
 
Crrt 2
Crrt  2Crrt  2
Crrt 2
 
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt 2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt  2CONTINUOUS RENAL REPLACEMENT THERAPY Crrt  2
CONTINUOUS RENAL REPLACEMENT THERAPY Crrt 2
 
Renal replacement therapy
Renal replacement therapyRenal replacement therapy
Renal replacement therapy
 
AN OVERVIEW OF DIALYSIS
AN OVERVIEW OF DIALYSISAN OVERVIEW OF DIALYSIS
AN OVERVIEW OF DIALYSIS
 
Introduction
IntroductionIntroduction
Introduction
 
Renal replacement therapies(RRT) - Medicine - RDT
Renal replacement therapies(RRT) - Medicine - RDTRenal replacement therapies(RRT) - Medicine - RDT
Renal replacement therapies(RRT) - Medicine - RDT
 

More from Dr. Ramesh Bhandari

Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity testsDr. Ramesh Bhandari
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infectionsDr. Ramesh Bhandari
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDr. Ramesh Bhandari
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsDr. Ramesh Bhandari
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthDr. Ramesh Bhandari
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health MissionDr. Ramesh Bhandari
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceDr. Ramesh Bhandari
 

More from Dr. Ramesh Bhandari (20)

Designing Protocol.pdf
Designing Protocol.pdfDesigning Protocol.pdf
Designing Protocol.pdf
 
Communicable diseases
Communicable diseasesCommunicable diseases
Communicable diseases
 
Causality Assessment ADR.pdf
Causality Assessment ADR.pdfCausality Assessment ADR.pdf
Causality Assessment ADR.pdf
 
Microbiological culture sensitivity tests
Microbiological culture sensitivity testsMicrobiological culture sensitivity tests
Microbiological culture sensitivity tests
 
Respiratory and Intestinal infections
Respiratory and Intestinal infectionsRespiratory and Intestinal infections
Respiratory and Intestinal infections
 
Epidemiology
EpidemiologyEpidemiology
Epidemiology
 
Microbiology
MicrobiologyMicrobiology
Microbiology
 
Nutrition and Food
Nutrition and FoodNutrition and Food
Nutrition and Food
 
Effect of environment on health
Effect of environment on healthEffect of environment on health
Effect of environment on health
 
Vaccine and immunity
Vaccine and immunityVaccine and immunity
Vaccine and immunity
 
Psychosocial pharmacy
Psychosocial pharmacyPsychosocial pharmacy
Psychosocial pharmacy
 
Nutrition
NutritionNutrition
Nutrition
 
Mother and child health
Mother and child healthMother and child health
Mother and child health
 
Demography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methodsDemography, demographic cycle and family planning methods
Demography, demographic cycle and family planning methods
 
National health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development GoalsNational health policy, MDGs, SDPs, and FIP Development Goals
National health policy, MDGs, SDPs, and FIP Development Goals
 
Concept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of healthConcept, Dimension, Determinants, and Indicators of health
Concept, Dimension, Determinants, and Indicators of health
 
Social pharmacy, National Health Mission
Social pharmacy, National Health MissionSocial pharmacy, National Health Mission
Social pharmacy, National Health Mission
 
Safety Data Generation
Safety Data GenerationSafety Data Generation
Safety Data Generation
 
ICH Guidelines for Pharmacovigilance
ICH Guidelines for PharmacovigilanceICH Guidelines for Pharmacovigilance
ICH Guidelines for Pharmacovigilance
 
Pharmacovigilance methods
Pharmacovigilance methodsPharmacovigilance methods
Pharmacovigilance methods
 

Recently uploaded

Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfPatidar M
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptxmary850239
 
Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Seán Kennedy
 
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfInclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfTechSoup
 
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxINTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxHumphrey A Beña
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptxiammrhaywood
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George
 
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfVirtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfErwinPantujan2
 
Concurrency Control in Database Management system
Concurrency Control in Database Management systemConcurrency Control in Database Management system
Concurrency Control in Database Management systemChristalin Nelson
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptxmary850239
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Celine George
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPCeline George
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)lakshayb543
 
ClimART Action | eTwinning Project
ClimART Action    |    eTwinning ProjectClimART Action    |    eTwinning Project
ClimART Action | eTwinning Projectjordimapav
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17Celine George
 
ICS2208 Lecture6 Notes for SL spaces.pdf
ICS2208 Lecture6 Notes for SL spaces.pdfICS2208 Lecture6 Notes for SL spaces.pdf
ICS2208 Lecture6 Notes for SL spaces.pdfVanessa Camilleri
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4MiaBumagat1
 

Recently uploaded (20)

FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptxFINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
FINALS_OF_LEFT_ON_C'N_EL_DORADO_2024.pptx
 
Active Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdfActive Learning Strategies (in short ALS).pdf
Active Learning Strategies (in short ALS).pdf
 
Paradigm shift in nursing research by RS MEHTA
Paradigm shift in nursing research by RS MEHTAParadigm shift in nursing research by RS MEHTA
Paradigm shift in nursing research by RS MEHTA
 
4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx4.18.24 Movement Legacies, Reflection, and Review.pptx
4.18.24 Movement Legacies, Reflection, and Review.pptx
 
Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...Student Profile Sample - We help schools to connect the data they have, with ...
Student Profile Sample - We help schools to connect the data they have, with ...
 
INCLUSIVE EDUCATION PRACTICES FOR TEACHERS AND TRAINERS.pptx
INCLUSIVE EDUCATION PRACTICES FOR TEACHERS AND TRAINERS.pptxINCLUSIVE EDUCATION PRACTICES FOR TEACHERS AND TRAINERS.pptx
INCLUSIVE EDUCATION PRACTICES FOR TEACHERS AND TRAINERS.pptx
 
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdfInclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
Inclusivity Essentials_ Creating Accessible Websites for Nonprofits .pdf
 
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxINTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptx
 
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptxAUDIENCE THEORY -CULTIVATION THEORY -  GERBNER.pptx
AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptx
 
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17
 
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfVirtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdf
 
Concurrency Control in Database Management system
Concurrency Control in Database Management systemConcurrency Control in Database Management system
Concurrency Control in Database Management system
 
4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx4.16.24 21st Century Movements for Black Lives.pptx
4.16.24 21st Century Movements for Black Lives.pptx
 
Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17Field Attribute Index Feature in Odoo 17
Field Attribute Index Feature in Odoo 17
 
How to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERPHow to do quick user assign in kanban in Odoo 17 ERP
How to do quick user assign in kanban in Odoo 17 ERP
 
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
Visit to a blind student's school🧑‍🦯🧑‍🦯(community medicine)
 
ClimART Action | eTwinning Project
ClimART Action    |    eTwinning ProjectClimART Action    |    eTwinning Project
ClimART Action | eTwinning Project
 
How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17How to Add Barcode on PDF Report in Odoo 17
How to Add Barcode on PDF Report in Odoo 17
 
ICS2208 Lecture6 Notes for SL spaces.pdf
ICS2208 Lecture6 Notes for SL spaces.pdfICS2208 Lecture6 Notes for SL spaces.pdf
ICS2208 Lecture6 Notes for SL spaces.pdf
 
ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4ANG SEKTOR NG agrikultura.pptx QUARTER 4
ANG SEKTOR NG agrikultura.pptx QUARTER 4
 

Extracorporeal removal of drugs

  • 1. E X T R A C O R P O R E A L R E M O V A L O F D R U G S D R . R A M E S H B H A N D A R I A S S T. P R O F E S S O R K L E C O L L E G E O F P H A R M A C Y, B E L A G AV I
  • 2. INTRODUCTION • Patients with end-stage renal disease (ESRD) and those who have become intoxicated with a drug as a result of drug overdose require supportive treatment to remove the accumulated drug and its metabolites. • Several methods are available for the extracorporeal removal of drugs, including:  Dialysis,  Hemoperfusion, and  Hemofiltration.
  • 3. INTRODUCTION • Objective:  rapidly remove the undesirable drugs and metabolites from the body without disturbing the fluid and electrolyte balance in the patient. • Patients with impaired renal function may be taking other medication concurrently. For these patients, dosage adjustment may be needed to replace drug loss during extracorporeal drug and metabolite removal.
  • 4. DIALYSIS • Dialysis is an artificial process in which the accumulated drugs or waste metabolites is removed by diffusion from the body into the dialysis fluid. • Two common dialysis treatments are hemodialysis and peritoneal dialysis.
  • 5. DIALYSIS • The principle: Uremic blood or fluid is equilibrated with the dialysis fluid across a dialysis membrane, waste metabolites from the patient’s blood or fluid diffuse into the dialysis fluid and are removed. The dialysate is balanced with electrolytes and with respect to osmotic pressure. The dialysate contains water, dextrose, electrolytes (potassium, sodium, chloride, bicarbonate, acetate, calcium, etc), and other elements similar to normal body fluids without the toxins.
  • 6. HEMODIALYSIS • uses a dialysis machine and filters blood through an artificial membrane. • requires access to the blood vessels to allow the blood to flow to the dialysis machine and back to the body. • For temporary access, a shunt is created in the arm, with one tube inserted into an artery and another tube inserted into a vein. The tubes are joined above the skin. • For permanent access to the blood vessels, an arteriovenous fistula or graft is created by a surgical procedure to allow access to the artery and vein.
  • 7. HEMODIALYSIS • At the start of the hemodialysis procedure, an arterial needle allows the blood to flow to the dialysis machine, and blood is returned to the patient to the venous side. Heparin is used to prevent blood clotting during the dialysis period.
  • 8. HEMODIALYSIS Indications: • When rapid removal of the drug from the body is important, as in overdose or poisoning. • End-stage renal failure. • Early dialysis is appropriate for patients with acute renal failure in whom resumption of renal function can be expected. • Renal transplanted.
  • 9. HEMODIALYSIS Drugs widely distributed are dialyzed more slowly. Drugs with largeVd Less than 500 are easily dialyzed. Molecular Weight Highly bound drugs are not dialyzed. (eg Propanolol) Protein binding Insoluble or fat soluble drugs are not dialyzed. (eg: Glutethimide) Water Solubility Factors Affecting Dialyzabillity of the drugs
  • 10. HEMODIALYSIS Factors Affecting Dialyzability of the drugs Characteristics of the dialysis machine Duration and frequency Transmembrane pressure Dialysis membrane Dialysate Blood flow rate
  • 11. PERITONEAL DIALYSIS • Peritoneal dialysis uses the peritoneal membrane in the abdomen as the filter. • The peritoneum membrane provides a large natural surface area for diffusion of approximately 1–2 m2 in adults; it is permeable to solutes of molecular weights ≤30,000 Dalton. • However, only a small portion of the total splanchnic blood flow (70 mL/min out of 1200 mL/min at rest) comes into contact with the peritoneum and gets dialyzed. • Placement of a peritoneal catheter is surgically simpler than hemodialysis and does not require vascular surgery and heparinization
  • 12. PERITONEAL DIALYSIS • The dialysis fluid is pumped into the peritoneal cavity, where waste metabolites in the body fluid are discharged rapidly. The dialysate is drained and fresh dialysate is reinstilled and then drained periodically. • Slower drug clearance rates are obtained with peritoneal dialysis compared to hemodialysis, and thus longer dialysis time is required. Fig: Side view of Peritoneal dialysis
  • 13. CONTINUOUS AMBULATORY PERITONEAL DIALYSIS • Most common form of peritoneal dialysis. • Many diabetic patients become uremic as a result of lack of control of their disease so the objective is to remove accumulated urea and other metabolic waste in the body.
  • 14. CONTINUOUS AMBULATORY PERITONEAL DIALYSIS  About 2 L of dialysis fluid is instilled into the peritoneal cavity of the patient through a surgically placed resident catheter.  The catheter is sealed and the patient is able to continue in an ambulatory mode.  Every 4–6 hours, the fluid is emptied from the peritoneal cavity and replaced with fresh dialysis fluid.  The technique uses about 2 L of dialysis fluid; it does not require a dialysis machine and can be performed at home.
  • 15. HEMOPERFUSION  Hemoperfusion is the process of removing drug by passing the blood from the patient through an adsorbent material and back to the patient.  Hemoperfusion is a useful procedure for rapid drug removal in accidental poisoning and drug overdose.  Because the drug molecules in the blood are in direct contact with the adsorbent material, any molecule that has great affinity for the adsorbent material will be removed.
  • 16. HEMOPERFUSION  The two main adsorbents used in hemoperfusion include (1) activated charcoal, which adsorbs both polar and nonpolar drug, and (2) Amberlite resins.  Amberlite resins, such as Amberlite XAD-2 and Amberlite XAD- 4, are available as insoluble polymeric beads, with each bead containing an agglomerate of cross-linked polystyrene microspheres.  The Amberlite resins have a greater affinity for nonpolar organic molecules than activated charcoal.
  • 17. HEMOPERFUSION  The important factors for drug removal by hemoperfusion include • affinity of the drug for the adsorbent, • surface area of the adsorbent, • absorptive capacity of the adsorbent, • rate of blood flow through the adsorbent, and • the equilibration rate of the drug from the peripheral tissue into the blood.
  • 18. HEMOFILTRATION  An alternative to hemodialysis and hemoperfusion is hemofiltration.  Hemofiltration is a process by which fluids, electrolytes, and small-molecular-weight substances are removed from the blood by means of low-pressure flow through hollow artificial fibers or flat-plate membranes.  Because fluid is also filtered out of the plasma during hemofiltration, replacement fluid is administered to the patient for volume replacement.
  • 19. HEMOFILTRATION  Hemofiltration is a slow, continuous filtration process that removes nonprotein-bound small molecules from the blood by convective mass transport.  The clearance of the drug depends on the sieving coefficient and ultrafiltration rate. Hemofiltration provides a creatinine clearance of approximately 10 mL/min and may have limited use for drugs that are widely distributed in the body, such as aminoglycosides, cephalosporines, and acyclovir.  A major problem with this method is the formation of blood clots within the hollow filter fibres.
  • 20. CONTINUOUS RENAL REPLACEMENT THERAPY • Because of the initial loss of fluid that results during hemofiltration, intermittent hemofiltration results in concentration of red blood cells in the resulting reduced plasma volume. • Therefore, blood becomes more viscous with a high hematocrit and high colloid osmotic pressure at the distal end of the hemofilter. Predilution may be used to circumvent this problem, but this method is rarely used because of cost and inefficiency.
  • 21. CONTINUOUS RENAL REPLACEMENT THERAPY • Continuous replacement therapy allows ongoing removal of fluid and toxins by relying on a patient’s own blood pressure to pump blood through a filter. • The continuous filtration is better tolerated by patients than intermittent therapy and provides optimal control of circulating volumes and ongoing toxin removal.
  • 22. CONTINUOUS RENAL REPLACEMENT THERAPY Continuous renal replacement therapy (CRRT) includes:  Continuous veno-venous hemofiltration (CVVH) and  Continuous arteriovenous hemofiltration (CAVH)